US REGULATORY RECORDS
- FDA DMF records
- 4
- Active (A)
- 3
- Inactive (I)
- 1
FDA list cutoff:
ACTIVE PHARMACEUTICAL INGREDIENT
Review Nilotinib API records for sourcing and regulatory due diligence. Compare FDA Drug Master File holders and activity codes, then check the chemical form and identifiers before requesting documentation.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
This profile uses the free-base identity, CAS 641571-10-0. FDA records are selected by reported subject. The workbook has no CAS field to verify the chemical form of an individual filing.
The supplied FDA snapshot contains 4 Type II records with the subject NILOTINIB. Browse the free sample or subscribe to search, filter and export the complete set.
FDA list cutoff:
The counts describe filings at the snapshot cutoff. Confirm the current activity status with FDA and the material specification with the holder before relying on a record.
$19.00 per month
$149.00 per year
Billed $149.00 every year
Nilotinib coverage: 4 FDA DMF records. The free CSV sample contains the preview rows.
One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product.
US REGULATORY RECORDS
Compare DMF numbers, reported holders, initial submission dates and activity status. The holder name identifies the party listed in the filing. Confirm the manufacturing site separately during qualification.
3Active (A)
1Inactive (I)
FDA uses A for active and I for inactive. An active entry alone does not establish permission to reference the file, an approved supplier or an available batch.
Free previewShowing 3 sample records of 4.
Free preview
More records available with a subscription: 1.
The FDA substance record identifies Nilotinib free base by CAS 641571-10-0 and UNII F41401512X and lists AMN-107 as a synonym. The TASIGNA label identifies the drug substance used in the finished capsules as nilotinib monohydrochloride monohydrate. The October 5, 2026 China CDE export has six related entries, all named 盐酸尼洛替尼 (nilotinib hydrochloride). The export does not identify the hydrate form of those entries.
The formula and molecular weight below describe the free base. When comparing specifications, check whether the assay is expressed as the free base or as the salt, and whether it is corrected for water content. Verify the stated hydrate or solid form against the intended material.
The CAS number is 641571-10-0. FDA identifies this substance with UNII F41401512X. Use the CAS and stated chemical form together when requesting a material specification.
The hydrochloride pairs the protonated base with chloride. TASIGNA uses the monohydrochloride monohydrate and expresses capsule strength as the equivalent amount of anhydrous free base. The CDE name indicates the hydrochloride salt and gives no specific hydrate or CAS number. Those registrations are outside this free-base record set.
The Q2 2026 workbook contains 4 Type II entries with NILOTINIB as the full subject after trimming. Type II also covers intermediates and finished drug products, so the subject is checked separately. The file gives no CAS field for independent confirmation.
An A code indicates that the DMF was active in the FDA snapshot. FDA reviews the technical contents in connection with an application that references the DMF. The activity code does not indicate FDA approval or confirm that the holder will authorize a reference.
Confirm the DMF number, the material form and assay basis, and the manufacturing site that would supply the intended batch. Request the applicable specification and batch certificate of analysis. If your application will reference the file, ask the holder about a letter of authorization.
Official substance references, source snapshots and FDA guidance for interpreting the records.
U.S. Food and Drug Administration
Identifies the free base by its CAS number, UNII, formula and AMN-107 synonym.
“641571-10-0”
U.S. Food and Drug Administration
Synonyms and Mappings in FDA UNII record F41401512X.
National Center for Biotechnology Information
Supplies the free-base formula and computed molecular weight.
“529.5 g/mol”
National Center for Biotechnology Information
Molecular Weight in the Computed Properties table for PubChem CID 644241.
U.S. National Library of Medicine
Describes the salt hydrate in the finished capsules and distinguishes it from the anhydrous free base used to express strength.
“in the form of monohydrochloride monohydrate”
U.S. National Library of Medicine
Section 11, Description, of the TASIGNA prescribing information hosted by DailyMed.
U.S. Food and Drug Administration
The supplied workbook contains the selected filings at the June 30, 2026 cutoff. The official list page may show a newer quarter.
“NILOTINIB”
U.S. Food and Drug Administration
Reported SUBJECT of the four selected Type II filings in worksheet 2Q2026-EXCEL.
U.S. Food and Drug Administration
Explains how DMFs can be referenced and how FDA reviews their contents alongside applications.
“Are neither approved nor disapproved.”
U.S. Food and Drug Administration
FDA explanation of Drug Master Files and review of applications that reference them.
U.S. Food and Drug Administration
Shows why Type II classification alone does not establish that a filing covers the free base.
“Drug Substance, Drug Substance Intermediate”
U.S. Food and Drug Administration
FDA Type II Drug Master File category heading.
Center for Drug Evaluation, National Medical Products Administration
The supplied export names all six related registrations as nilotinib hydrochloride.
“盐酸尼洛替尼”
Center for Drug Evaluation, National Medical Products Administration
Reported substance name in the supplied eleven-column CDE API registry export.
Use the free records to compare DMF holders and activity. Subscribe to search, filter and export the complete Nilotinib dataset from the supplied FDA snapshot.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
Include the DMF number or field in question and a link to the supporting source.
Email APIRFQ support